Trius Therapeutics Secures $25M Equity Financing
Trius Therapeutics, Inc. (Nasdaq: TSRX) announced today that it has obtained a committed equity financing facility under which it may from time to time sell up to $25 million of its registered common stock to Terrapin Opportunity, L.P., over a 24-month period. Trius is not obligated to utilize any of the $25 million facility and remains free to enter into and consummate other equity and debt financing transactions, subject to certain restrictions.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.